Products Categories
CAS No.: | 58786-99-5 |
---|---|
Name: | Butorphanol tartrate |
Molecular Structure: | |
Formula: | C21H29NO2.C4H6O6 |
Molecular Weight: | 477.61 |
Synonyms: | Butorphanol tartrate (JAN/USP);Morphinan-3,14-diol,17-(cyclobutylmethyl)-,(2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt);Stadol;Moradol;Stadol (TN); |
EINECS: | 261-443-5 |
Melting Point: | 217-219° |
Boiling Point: | 722.3 °C at 760 mmHg |
Flash Point: | 390.7 °C |
Hazard Symbols: | Xn |
Risk Codes: | 22-63 |
Safety: | 22-26-36/37/39 |
Transport Information: | UN 1544 |
PSA: | 158.76000 |
LogP: | 1.18090 |
Chemistry informtion about Butorphanol Tartrate (CAS NO.58786-99-5) is:
IUPAC Name: Pentyl nitrite
Synonyms: Morphinan-3,14-Diol, 17-(Cyclobutylmethyl)-, (S-(R*,R*))-2,3-Dihydroxybutanedioate (1:1) (Salt);Morphinan-3,14-Diol, 17-(Cyclobutylmethyl)-,(S-(R,R))-2,3-Dihydroxybutanedioate (1:1) (Salt);Morphinan-3,14-Diol,17-(Cyclobutylmethyl)-,(S-(R*,R*))-2,3-Dihydroxybutanedi;Oate(1:1)(Salt);Stadol;Torate;Torbutrol;Butorphanol Tartrate
MF: C25H35NO8
MW: 477.55
EINECS: 261-443-5
Flash Point: 265.9 °C
Boiling Point: 507.3 °C at 760 mmHg
Vapour Pressure: 4.11E-11 mmHg at 25°C
Enthalpy of Vaporization: 81.85 kJ/mol
Storage temp.: 2-8°C
Following is the molecular structure of Butorphanol Tartrate (CAS NO.58786-99-5) is:
Butorphanol Tartrate (CAS NO.58786-99-5) is a strong narcotic analgesic (pain reliever) used to control pain. It has also been used to treat migraine headaches.
It is available in the U.S. as a generic drug; it is available in various nations under one of any number of trade names, including Moradol and Beforal (Brand name Stadol no longer available in the US); veterinary trade names include Butorphic, Dolorex, Morphasol, Torbugesic, and Torbutrol.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | intramuscular | 17mg/kg (17mg/kg) | Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 16, Pg. 474, 1978. | |
dog | LD50 | intravenous | 10mg/kg (10mg/kg) | Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 16, Pg. 474, 1978. | |
dog | LD50 | oral | > 50mg/kg (50mg/kg) | Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 19, 1979. | |
monkey | LD50 | oral | > 50mg/kg (50mg/kg) | Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 19, 1979. | |
mouse | LD50 | intramuscular | 208mg/kg (208mg/kg) | behavioral: somnolence (general depressed activity) behavioral: convulsions or effect on seizure threshold lungs, thorax, or respiration: dyspnea | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 145, 1982. |
mouse | LD50 | intraperitoneal | 192mg/kg (192mg/kg) | behavioral: somnolence (general depressed activity) behavioral: convulsions or effect on seizure threshold lungs, thorax, or respiration: dyspnea | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 145, 1982. |
mouse | LD50 | intravenous | 36mg/kg (36mg/kg) | behavioral: somnolence (general depressed activity) lungs, thorax, or respiration: dyspnea behavioral: convulsions or effect on seizure threshold | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 145, 1982. |
mouse | LD50 | oral | 395mg/kg (395mg/kg) | Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 16, Pg. 474, 1978. | |
mouse | LD50 | subcutaneous | 299mg/kg (299mg/kg) | behavioral: somnolence (general depressed activity) behavioral: convulsions or effect on seizure threshold behavioral: ataxia | Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 19, 1979. |
rat | LD50 | intramuscular | 255mg/kg (255mg/kg) | behavioral: somnolence (general depressed activity) behavioral: convulsions or effect on seizure threshold lungs, thorax, or respiration: dyspnea | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 145, 1982. |
rat | LD50 | intraperitoneal | 127mg/kg (127mg/kg) | behavioral: somnolence (general depressed activity) behavioral: convulsions or effect on seizure threshold lungs, thorax, or respiration: dyspnea | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 145, 1982. |
rat | LD50 | intravenous | 17mg/kg (17mg/kg) | Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 16, Pg. 474, 1978. | |
rat | LD50 | oral | 315mg/kg (315mg/kg) | behavioral: somnolence (general depressed activity) behavioral: convulsions or effect on seizure threshold lungs, thorax, or respiration: dyspnea | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 145, 1982. |
rat | LD50 | subcutaneous | 425mg/kg (425mg/kg) | behavioral: somnolence (general depressed activity) behavioral: convulsions or effect on seizure threshold lungs, thorax, or respiration: dyspnea | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 145, 1982. |
Poison by ingestion, subcutaneous, intramuscular, intravenous, and intraperitoneal routes. An experimental teratogen. Other experimental reproductive effects. An analgesic. When heated to decomposition it emits toxic fumes of NOx.
Hazard Codes:
Xn
Risk Statements:
R22:Harmful if swallowed.
R63:Possible risk of harm to the unborn child.
Safety Statements:
S22:Do not breathe dust.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.
RIDADR: 1544
WGK Germany: 3
RTECS: QC7795000
HazardClass: 6.1(a)
PackingGroup: II
To protect yourself, you can put on eyeshields, faceshields, full-face particle respirator type N100 (US), gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges.
It exhibits partial agonist and antagonist activity at the μ opioid receptor and agonist activity at the κ opioid receptor. Stimulation of these receptors on central nervous system neurons causes an intracellular inhibition of adenylate cyclase, closing of influx membrane calcium channels, and opening of membrane potassium channels. This leads to hyperpolarization of the cell membrane potential and suppression of action potential transmission of ascending pain pathways. Because of its κ-agonist activity, at analgesic doses butorphanol increases pulmonary arterial pressure and cardiac work. Additionally, κ-agonism can cause dysphoria at therapeutic or supertherapeutic doses; this gives butorphanol a lower potential for abuse than other opioid drugs.